Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
- PMID: 12409337
- DOI: 10.1200/JCO.2002.10.088
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
Abstract
Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with critical roles in tumor angiogenesis. This article reviews the literature with regard to VEGF-A's multiple functions, the mechanisms by which it induces angiogenesis, and its current and projected roles in clinical oncology. VEGF-A is a multifunctional cytokine that is widely expressed by tumor cells and that acts through receptors (VEGFR-1, VEGFR-2, and neuropilin) that are expressed on vascular endothelium and on some other cells. It increases microvascular permeability, induces endothelial cell migration and division, reprograms gene expression, promotes endothelial cell survival, prevents senescence, and induces angiogenesis. Recently, VEGF-A has also been shown to induce lymphangiogenesis. Measurements of circulating levels of VEGF-A may have value in estimating prognosis, and VEGF-A and its receptors are potential targets for therapy. Recognized as the single most important angiogenic cytokine, VEGF-A has a central role in tumor biology and will likely have an important role in future approaches designed to evaluate patient prognosis. It may also become an important target for cancer therapy.
Similar articles
-
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.EXS. 1997;79:233-69. doi: 10.1007/978-3-0348-9006-9_10. EXS. 1997. PMID: 9002222 Review.
-
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.Cancer Res. 2003 Jun 15;63(12):3403-12. Cancer Res. 2003. PMID: 12810677
-
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor.Nat Med. 2001 May;7(5):569-74. doi: 10.1038/87895. Nat Med. 2001. PMID: 11329058
-
Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.Cancer Res. 1998 Mar 15;58(6):1278-84. Cancer Res. 1998. PMID: 9515816
-
Vascular permeability factor, tumor angiogenesis and stroma generation.Invasion Metastasis. 1994-1995;14(1-6):385-94. Invasion Metastasis. 1994. PMID: 7544775 Review.
Cited by
-
Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma.Front Oncol. 2022 Sep 23;12:993573. doi: 10.3389/fonc.2022.993573. eCollection 2022. Front Oncol. 2022. PMID: 36212393 Free PMC article. Review.
-
DPSCs treated by TGF-β1 regulate angiogenic sprouting of three-dimensionally co-cultured HUVECs and DPSCs through VEGF-Ang-Tie2 signaling.Stem Cell Res Ther. 2021 May 10;12(1):281. doi: 10.1186/s13287-021-02349-y. Stem Cell Res Ther. 2021. PMID: 33971955 Free PMC article.
-
Macromolecule extravasation-xenograft size matters: a systematic study using probe-based confocal laser endomicroscopy (pCLE).Mol Imaging Biol. 2013 Dec;15(6):693-702. doi: 10.1007/s11307-013-0641-z. Mol Imaging Biol. 2013. PMID: 23632953 Free PMC article.
-
Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.Clin Cancer Res. 2012 Jun 15;18(12):3328-39. doi: 10.1158/1078-0432.CCR-11-3000. Epub 2012 Apr 10. Clin Cancer Res. 2012. PMID: 22496203 Free PMC article.
-
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.Radiat Oncol. 2013 Apr 15;8:90. doi: 10.1186/1748-717X-8-90. Radiat Oncol. 2013. PMID: 23587311 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources